The agreement covers commercialization of vamorolone in Duchenne Muscular Dystrophy and rights to all potential future indications in North America. Total consideration to Santhera is up to USD 231 million (including equity investment), plus royalty payments from product sales, with near term cash proceeds for Santhera of USD 126 million.

Schellenberg Wittmer advised Santhera on the license agreement. The team included Philipp Groz and Alisa Zehner (both IP / Life Sciences), Marcel Jakob (Corporate/M&A), Michael Nordin and Tabea Elmer (both Tax).